Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with…

Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension

Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension#Innovations #High #Blood #Pressure #Intervention #Benefit…

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension…

The Blood Pressure Breakthrough: Mineralys Therapeutics’ Lorundrostat Shows Promise in Treating Uncontrolled Hypertension

In a major breakthrough for the medical community, Mineralys Therapeutics has announced positive topline results from…

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension #Mineralys #Therapeutics #Lorundrostat #Worth #Shot…

Recor Medical Statement on CMS National Coverage Analysis of Renal Denervation for the Treatment of Hypertension By Investing.com

Palo Alto, CA, Jan. 13, 2025 (GLOBE NEWSWIRE) — Recor Medical (TASE:), Inc. (Recor) and its…